tiprankstipranks
CL Earnings: Colgate-Palmolive Posts Strong Q3 Results amid Rising Product Demand
Market News

CL Earnings: Colgate-Palmolive Posts Strong Q3 Results amid Rising Product Demand

Story Highlights

Colgate-Palmolive reported better-than-expected results in the third quarter.

Colgate-Palmolive Co. (CL) reported better-than-expected results in the third quarter. The consumer products company reported adjusted earnings of $0.91 per share, an increase of 6% year-over-year, beating consensus estimates of $0.89 per share.

Don't Miss our Black Friday Offers:

The company posted net sales of $5.03 billion, up by 2.4% year-over-year, compared to consensus estimates of $5.01 billion.

CL’s CEO Comments on the Results

Colgate-Palmolive’s Chairman, President, and CEO, Noel Wallace, commented, “Every operating division delivered positive volume growth for the second consecutive quarter as we focus on increasing household penetration to drive category growth and market shares.”

Furthermore, consumers are increasingly spending on daily essentials compared to discretionary items amid rising costs. This trend has bolstered sales for consumer packaged goods companies like Colgate-Palmolive. This shift in spending has led to rising demand for the company’s oral care and hygiene products, despite a series of price increases.

CL Raises FY24 Guidance

Looking ahead, CL expects its net sales in FY24 to grow in the range of 3% to 5%, compared to its prior forecast of between 2% and 5%. Moreover, the company estimates its adjusted earnings will rise between 10% and 11%, versus its prior outlook of 8% to 11%.

Is CL a Buy?

Analysts remain cautiously optimistic about CL stock, with a Moderate Buy consensus rating based on nine Buys, seven Holds, and one Sell. Over the past year, CL has increased by more than 30%, and the average CL price target of $107.71 implies an upside potential of 8% from current levels. These analyst ratings are likely to change following CL’s results today.

See more CL analyst ratings

Related Articles
TheFlyColgate-Palmolive slips after FDA posts warning letter sent to Tom’s
TheFlyColgate Palmolive put volume heavy and directionally bearish
TheFlyCoinbase initiated, Edwards Lifesciences upgraded: Wall Street’s top analyst cal
Go Ad-Free with Our App